DOCSLIB.ORG

Platelet-Inspired Nanomedicine for the Hemostatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Platelet-Inspired Nanomedicine for the Hemostatic PLATELET-INSPIRED NANOMEDICINE FOR THE HEMOSTATIC MANAGEMENT OF BLEEDING COMPLICATIONS IN THROMBOCYTOPENIA AND TRAUMA by DASHAWN A. HICKMAN Submitted in partial fulfillment of the requirement for the degree of Doctor of Philosophy Department of Pathology CASE WESTERN RESERVE UNIVERSITY January, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of DaShawn A. Hickman candidate for the degree of Doctor of Philosophy*. Committee Chair Nicholas Ziats, PhD Committee Member Anirban Sen Gupta, PhD Committee Member James Anderson, MD, PhD Committee Member Agata Exner, PhD Committee Member Howard Meyerson, MD Committee Member Clive Hamlin, PhD Date of Defense August 16, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication I would like to dedicate my dissertation to my family who have always supported me and encouraged me to be great, especially my parents and siblings; my friends for setting the bar high and keeping my spirits higher, the MSTP entering class of 201l and my labmates. i Table of Contents Dedication ................................................................................................................... i List of Tables ............................................................................................................. ix List of Figures ............................................................................................................. x Acknowledgements .................................................................................................. xvi List of Abbreviations ................................................................................................ xvii Abstract ................................................................................................................ xxvii Chapter 1 : Bleeding Complications in Thrombocytopenia and Trauma ........................ 1 1.1 Introduction ..........................................................................................................1 1.2 Trauma ..................................................................................................................2 1.3 Thrombocytopenia.................................................................................................4 1.4 Complex Mechanism of Hemostasis .......................................................................7 1.5 Management of Traumatic Bleeding ..................................................................... 10 1.6 Acknowledgments ............................................................................................... 12 1.7 References ........................................................................................................... 12 Chapter 2 : Externally Administered (Topical and Intracavitary) Biomaterials and Advanced Technologies for Management of Traumatic Bleeding .............................. 28 2.1 Introduction ........................................................................................................ 28 2.2 Tourniquets ......................................................................................................... 28 2.3 Naturally derived biomaterials for hemostatic applications ................................... 30 ii 2.3.1 Absorptive and passively interactive materials in hemostatic technologies ......................... 31 2.3.2 Bioactive materials in hemostatic technologies .................................................................... 35 2.4 Synthetically derived hemostatic materials ........................................................... 52 2.5 Compression bandage technologies ...................................................................... 57 2.6 Combination systems and advanced technologies ................................................. 61 2.7 Hemostatic materials and technologies for intracavitary applications.................... 62 2.8 Discussion ............................................................................................................ 63 2.9 Acknowledgments ............................................................................................... 66 2.10 References ........................................................................................................... 66 Chapter 3 : Intravenously Administered Biomaterials and Advanced Technologies for Management of Traumatic Non-compressible Hemorrhage .................................... 110 3.1 Introduction ...................................................................................................... 110 3.2 Naturally derived intravascular pro-coagulant materials ..................................... 111 3.3 Synthetically derived pro-coagulant systems ...................................................... 114 3.4 Materials and technologies to enhance clot strength and stability ....................... 116 3.5 Materials and technologies for vascular embolization ......................................... 122 3.6 Natural platelet-derived systems ........................................................................ 124 3.7 Synthetic biomaterials-based platelet mimics and substitutes ............................. 134 3.8 Discussion .......................................................................................................... 139 3.9 Acknowledgments ............................................................................................. 143 iii 3.10 References ......................................................................................................... 143 Chapter 4 : Designing an Ideal Platelet-inspired System for the Intravenous Management of Traumatic Bleeding....................................................................... 166 4.1 Introduction ...................................................................................................... 166 4.2 Current State of Traumatic Bleeding Management .............................................. 167 4.3 Designing an Ideal System .................................................................................. 169 4.4 Design of SynthoPlateTM Nanoparticle System .................................................... 171 4.5 SynthoPlateTM In Vitro Evaluation ....................................................................... 173 4.6 In Vivo Evaluation of SynthoPlateTM In Thrombocytopenia Model ....................... 174 4.7 Discussion .......................................................................................................... 178 4.8 Acknowledgments ............................................................................................. 180 4.9 References ......................................................................................................... 181 Chapter 5 : Intravenous administration of synthetic platelets (SynthoPlate) in a mouse liver injury model of uncontrolled hemorrhage improves hemostasis ...................... 189 5.1 Introduction ...................................................................................................... 189 5.2 Materials and Methods ...................................................................................... 190 5.2.1 Animals ................................................................................................................................ 190 5.2.2 SynthoPlate Manufacture .................................................................................................... 190 5.2.3 Liver Laceration Model of Uncontrolled Hemorrhage and SynthoPlate Evaluation ........... 191 5.2.4 In Vivo Biodistribution of SynthoPlate Particles .................................................................. 193 5.2.5 Statistics............................................................................................................................... 194 iv 5.3 Results ............................................................................................................... 194 5.3.1 SynthoPlate Transfusion as a Pretreatment Results in Decreased Blood Loss and Improved Hemodynamics During Acute, Severe Hemorrhagic Shock ............................................................... 194 5.3.2 Systemic Biodistribution SynthoPlate Particles Following Liver Laceration ........................ 196 5.3.3 SynthoPlate Particles Reduce Blood Loss and Improve Hemodynamics in Mice in Hemorrhagic Shock ............................................................................................................................ 198 5.4 Discussion .......................................................................................................... 198 5.5 Authorship......................................................................................................... 203 5.6 Acknowledgement ............................................................................................. 203 5.7 Disclosure .......................................................................................................... 203 5.8 References ......................................................................................................... 204 Chapter 6 : Intravenous synthetic platelet (SynthoPlateTM) nanoconstructs reduce bleeding and improve ‘golden hour’ survival in a porcine model of traumatic arterial hemorrhage ........................................................................................................... 207 6.1 Introduction .....................................................................................................
Load more

Recommended publications
  • Recognizing When a Child's Injury Or Illness Is Caused by Abuse
    U.S. Department of Justice Office of Justice Programs Office of Juvenile Justice and Delinquency Prevention Recognizing When a Child’s Injury or Illness Is Caused by Abuse PORTABLE GUIDE TO INVESTIGATING CHILD ABUSE U.S. Department of Justice Office of Justice Programs 810 Seventh Street NW. Washington, DC 20531 Eric H. Holder, Jr. Attorney General Karol V. Mason Assistant Attorney General Robert L. Listenbee Administrator Office of Juvenile Justice and Delinquency Prevention Office of Justice Programs Innovation • Partnerships • Safer Neighborhoods www.ojp.usdoj.gov Office of Juvenile Justice and Delinquency Prevention www.ojjdp.gov The Office of Juvenile Justice and Delinquency Prevention is a component of the Office of Justice Programs, which also includes the Bureau of Justice Assistance; the Bureau of Justice Statistics; the National Institute of Justice; the Office for Victims of Crime; and the Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking. Recognizing When a Child’s Injury or Illness Is Caused by Abuse PORTABLE GUIDE TO INVESTIGATING CHILD ABUSE NCJ 243908 JULY 2014 Contents Could This Be Child Abuse? ..............................................................................................1 Caretaker Assessment ......................................................................................................2 Injury Assessment ............................................................................................................4 Ruling Out a Natural Phenomenon or Medical Conditions
    [Show full text]
  • COVID-19 Publications - Week 05 2021 1328 Publications
    Update February 1 - February 7, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 05 2021 1328 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With
    [Show full text]
  • Protocols for Injuries to the Eye Corneal Abrasion I
    PROTOCOLS FOR INJURIES TO THE EYE CORNEAL ABRASION I. BACKGROUND A corneal abrasion is usually caused by a foreign body or other object striking the eye. This results in a disruption of the corneal epithelium. II. DIAGNOSTIC CRITERIA A. Pertinent History and Physical Findings Patients complain of pain and blurred vision. Photophobia may also be present. Symptoms may not occur for several hours following an injury. B. Appropriate Diagnostic Tests and Examinations Comprehensive examination by an ophthalmologist to rule out a foreign body under the lids, embedded in the cornea or sclera, or penetrating into the eye. The comprehensive examination should include a determination of visual acuity, a slit lamp examination and a dilated fundus examination when indicated. III. TREATMENT A. Outpatient Treatment Topical antibiotics, cycloplegics, and pressure patch at the discretion of the physician. Analgesics may be indicated for severe pain. B. Duration of Treatment May require daily visits until cornea sufficiently healed, usually within twenty-four to seventy-two hours but may be longer with more extensive injuries. In uncomplicated cases, return to work anticipated within one to two days. The duration of disability may be longer if significant iritis is present. IV. ANTICIPATED OUTCOME Full recovery. CORNEAL FOREIGN BODY I. BACKGROUND A corneal foreign body most often occurs when striking metal on metal or striking stone. Auto body workers and machinists are the greatest risk for a corneal foreign body. Hot metal may perforate the cornea and enter the eye. Foreign bodies may be contaminated and pose a risk for corneal ulcers. II. DIAGNOSTIC CRITERIA A. Pertinent History and Physical Findings The onset of pain occurs either immediately after the injury or within the first twenty-four hours.
    [Show full text]
  • Skin Injuries – Can We Determine Timing and Mechanism?
    Skin injuries – can we determine timing and mechanism? Jo Tully VFPMS Seminar 2016 What skin injuries do we need to consider? • Bruising • Commonest accidental and inflicted skin injury • Basic principles that can be applied when formulating opinion • Abrasions • Lacerations }we need to be able to tell the difference • Incisions • Stabs/chops • Bite marks – animal v human / inflicted v ‘accidental’ v self-inflicted Our role…. We are often/usually/always asked…………….. • “What type of injury is it?” • “When did this injury occur?” • “How did this injury occur?” • “Was this injury inflicted or accidental?” • IS THIS CHILD ABUSE? • To be able to answer these questions (if we can) we need knowledge of • Anatomy/physiology/healing - injury interpretation • Forces • Mechanisms in relation to development, plausibility • Current evidence Bruising – can we really tell which bruises are caused by abuse? Definitions – bruising • BLUNT FORCE TRAUMA • Bruise =bleeding beneath intact skin due to BFT • Contusion = bruise in deeper tissues • Haematoma - extravasated blood filling a cavity (or potential space). Usually associated with swelling • Petechiae =Pinpoint sized (0.1-2mm) hemorrhages into the skin due to acute rise in venous pressure • medical causes • direct forces • indirect forces Medical Direct Indirect causes mechanical mechanical forces forces Factors affecting development and appearance of a bruise • Properties of impacting object or surface • Force of impact • Duration of impact • Site - properties of body region impacted (blood supply,
    [Show full text]
  • Medical Term for Scrape
    Medical Term For Scrape protozoologicalIncomprehensible Mack Willmott federalized fraction fermentation some decimeter and tickle after hishyphenated rusticator Thornie revengingly overtasks and owlishly. perforce. Zedekiah Lecherous and andbeseeched grippier. his focussing lobes challengingly or contritely after Mayor knee and previews angelically, unmasking Ttw is for scrape may require stitches to medications and support a knee sprains heal closed wounds such as terms at harvard medical history does not. This medical terms for scraping can be. Ancient Chinese medical treatment leaves lasting impressions. Lifting the cloth, gauze, or bandage to check on the wound may cause additional bleeding, so it is important to continue to maintain firm pressure over the abrasion. Many people with their expertise in cross section is the risk for teaching hospital but all are a scrape for their location. Please stand by, while we are checking your browser. It helps prepare the tooth for this procedure and can also be used on the root of a tooth is needed. Abrasion this grant the medical term for scraped skin This happens when an injury scrapes off the particular layer of talking skin A person may say the he. How to scrape for scrapes and ice pack or treatment may be avoided in terms as a term for dentures that gives back to treat a lawyer. Antibiotics For Wound Infection PlushCare. Gua sha Scraping of low is able to relieve pain more ease. Awareness of your surroundings and paying close trip to in you need doing my help manual the likelihood of an accidental scrape, plane, or injury. Please consult your health care provider with any questions or concerns you may have regarding your condition.
    [Show full text]
  • Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
    pharmaceutics Article Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes Franklin Afinjuomo 1, Thomas G. Barclay 1, Ankit Parikh 1, Yunmei Song 1, Rosa Chung 1, Lixin Wang 1, Liang Liu 1, John D. Hayball 1, Nikolai Petrovsky 2,3 and Sanjay Garg 1,* 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia; olumide.afi[email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (Y.S.); [email protected] (R.C.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 2 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; nikolai.petrovsky@flinders.edu.au 3 Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia * Correspondence: [email protected]; Tel.: +61-8-8302-1567 Received: 26 April 2019; Accepted: 16 May 2019; Published: 22 May 2019 Abstract: The propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less effective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker.
    [Show full text]
  • WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T (51) International Patent Classification: SHENIA, Iaroslav Viktorovych [UA/UA]; Feodosiyskyy A61L 15/44 (2006.01) A61L 26/00 (2006.01) lane, 14-a, kv. 65, Kyiv, 03028 (UA). A61L 15/54 (2006.01) (74) Agent: BRAGARNYK, Oleksandr Mykolayovych; str. (21) International Application Number: Lomonosova, 60/5-43, Kyiv, 03189 (UA). PCT/UA20 16/0000 19 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2016 (15.02.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, a 2015 01285 16 February 2015 (16.02.2015) UA PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, u 2015 01288 16 February 2015 (16.02.2015) UA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Advances in Nanomaterials in Biomedicine
    nanomaterials Editorial Advances in Nanomaterials in Biomedicine Elena Ryabchikova Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, 8 Lavrentiev Ave., 630090 Novosibirsk, Russia; [email protected] Keywords: nanotechnology; nanomedicine; biocompatible nanomaterials; diagnostics; nanocarriers; targeted drug delivery; tissue engineering Biomedicine is actively developing a methodological network that brings together biological research and its medical applications. Biomedicine, in fact, is at the front flank of the creation of the latest technologies for various fields in medicine, and, obviously, nanotechnologies occupy an important place at this flank. Based on the well-known breadth of the concept of “Biomedicine”, the boundaries of the Special Issue “Advances in Nanomaterials in Biomedicine” were not limited, and authors could present their work from various fields of nanotechnology, as well as new methods and nanomaterials intended for medical applications. This approach made it possible to make public not only specific developments, but also served as a kind of mirror reflecting the most active interest of researchers in a particular field of application of nanotechnology in biomedicine. The Special Issue brought together more than 110 authors from different countries, who submitted 11 original research articles and 7 reviews, and conveyed their vision of the problems of nanomaterials in biomedicine to the readers. A detailed and well-illustrated review on the main problems of nanomedicine in onco-immunotherapy was presented by Acebes-Fernández and co-authors [1]. It should be noted that the review is not limited to onco-immunotherapy, and gives a complete understanding of nanomedicine in general, which is useful for those new to this field.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Introducing Bionanotechnology Into Undergraduate Biomedical Engineering
    AC 2009-504: INTRODUCING BIONANOTECHNOLOGY INTO UNDERGRADUATE BIOMEDICAL ENGINEERING Aura Gimm, Duke University J. Aura Gimm is Assistant Professor of the Practice and Associated Director of Undergraduate Studies in the Department of Biomedical Engineering at Duke University. She teaches courses in biomaterials, thermodynamics/kinetics, engineering design, and a new course in bionanotechnology. Dr. Gimm received her S.B. in Chemical Engineering and Biology from MIT, and her Ph.D. in Bioengineering from UC-Berkeley. Page 14.802.1 Page © American Society for Engineering Education, 2009 Introducing Bionanotechnology in Undergraduate Biomedical Engineering Abstract As a part of the NSF-funded Nanotechnology Undergraduate Education Program, we have developed and implemented a new upper division elective course in Biomedical Engineering titled “Introduction to Bionanotechnology Engineering”. The pilot course included five hands- on “Nanolab” modules that guided students through specific aspects of nanomaterials and engineering design in addition to lecture topics such as scaling effects, quantum effects, electrical/optical properties at nanoscale, self-assembly, nanostructures, nanofabrication, biomotors, biological designing, biosensors, etc. Students also interacted with researchers currently working in the areas of nanomedicine, self-assembly, tribiology, and nanobiomaterials to learn first-hand the engineering and design challenges. The course culminated with research or design proposals and oral presentations that addressed specific engineering/design issues facing nanobiotechnology and/or nanomedicine. The assessment also included an exam (only first offering), laboratory write-ups, reading of research journal articles and analysis, and an essay on ethical/societal implications of nanotechnology, and summative questionnaire. The course exposed students to cross-disciplinary intersections that occur between biomedical engineering, materials science, chemistry, physics, and biology when working at the nanoscale.
    [Show full text]
  • Nanotechnology in Regenerative Medicine: the Materials Side
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UPCommons. Portal del coneixement obert de la UPC Review Nanotechnology in regenerative medicine: the materials side Elisabeth Engel, Alexandra Michiardi, Melba Navarro, Damien Lacroix and Josep A. Planell Institute for Bioengineering of Catalonia (IBEC), Department of Materials Science, Technical University of Catalonia, CIBER BBN, Barcelona, Spain Regenerative medicine is an emerging multidisciplinary structures and materials with nanoscale features that can field that aims to restore, maintain or enhance tissues mimic the natural environment of cells, to promote certain and hence organ functions. Regeneration of tissues can functions, such as cell adhesion, cell mobility and cell be achieved by the combination of living cells, which will differentiation. provide biological functionality, and materials, which act Nanomaterials used in biomedical applications include as scaffolds to support cell proliferation. Mammalian nanoparticles for molecules delivery (drugs, growth fac- cells behave in vivo in response to the biological signals tors, DNA), nanofibres for tissue scaffolds, surface modifi- they receive from the surrounding environment, which is cations of implantable materials or nanodevices, such as structured by nanometre-scaled components. Therefore, biosensors. The combination of these elements within materials used in repairing the human body have to tissue engineering (TE) is an excellent example of the reproduce the correct signals that guide the cells great potential of nanotechnology applied to regenerative towards a desirable behaviour. Nanotechnology is not medicine. The ideal goal of regenerative medicine is the in only an excellent tool to produce material structures that vivo regeneration or, alternatively, the in vitro generation mimic the biological ones but also holds the promise of of a complex functional organ consisting of a scaffold made providing efficient delivery systems.
    [Show full text]